株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

コンパニオン診断の世界市場の将来予測

Global Companion Diagnostics Market Forecast 2018-2026

発行 Inkwood Research 商品コード 718313
出版日 ページ情報 英文 156 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
コンパニオン診断の世界市場の将来予測 Global Companion Diagnostics Market Forecast 2018-2026
出版日: 2018年10月08日 ページ情報: 英文 156 Pages
概要

当レポートでは、世界のコンパニオン診断の関連市場の将来展望について分析し、技術の概要や市場の構造、主な市場促進・抑制要因、全体的な市場規模の動向見通し (今後9年間分)、製品/サービス別・症状別・エンドユーザー別・技術別および地域別の詳細動向、関連産業との連関構造と市場機会、市場競争環境、主要企業のプロファイルなどを調査しております。

第1章 分析範囲

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場の決定要因

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 課題

第5章 市場区分

  • 製品・サービス別市場 (今後9年間分)
    • アッセイキット・試薬
    • ソフトウェア・サービス
  • 症状別の市場 (今後9年間分)
    • 腫瘍
    • 神経疾患
    • 感染症
    • その他の症状
  • エンドユーザーの市場 (今後9年間分)
    • 製薬企業/バイオ医薬品企業
    • 参考検査室
    • その他のエンドユーザー
  • 技術別の市場 (今後9年間分)
    • in situハイブリダイゼーション (ISH)
    • ポリメラーゼ連鎖反応 (PCR)
    • 免疫組織化学 (IHC)
    • 次世代シーケンシング (NGS)
    • その他の技術

第6章 主な分析指標

  • ポーターのファイブフォース分析
  • コンパニオン診断の定義・分類
  • サプライチェーン分析
  • 主な購入基準
  • 規制枠組み
  • 推計分析

第7章 地域別分析

  • 北米 (米国、カナダ)
  • 欧州 (英国、フランス、ドイツ、スペイン、イタリアなど)
  • アジア太平洋地域 (中国、インド、日本、オーストラリア、韓国など)
  • 他の国々 (RoW:ラテンアメリカ、中東・アフリカ)

第8章 企業プロファイル

  • 競争環境
  • ABBOTT LABORATORIES.
    • 企業概要
    • 製品ポートフォリオ
    • SCOT分析
    • 戦略展開状況
  • ALMAC GROUP
  • ARUP LABORATORIES
  • BIOCARTIS
  • BIOMERIEUX S.A
  • DANAHER CORPORATION
  • GE HEALTHCARE
  • GENOMIC HEALTH
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS (A HOFFMANN-LA ROCHE AG DIVISON)
  • シスメックス
  • THERMO FISHER SCIENTIFIC, INC.
目次
Product Code: 22180

KEY FINDINGS

The global companion diagnostics market is driven by factors such as the widespread of cancer disease across the globe, high demand for target therapies and strategic initiatives for companion diagnostics test development. By the end of the forecast period of 2018-2026, the market is expected to rise with a 18.45% CAGR.

MARKET INSIGHTS

The global companion diagnostics market is segmented on the basis of technology, products and services, indications and end-users. The technology segment includes polymerase chain reaction, in situ hybridization, immunohistochemistry, next-generation sequencing and other technologies. The product and service segment includes assay kits and reagents and software and service. The indication segment is further classified into oncology, neurology, infectious diseases and other indications. The market caters to end-users like pharmaceutical and biopharmaceutical companies, reference laboratories and other end users.

REGIONAL INSIGHTS

The global companion diagnostics market covers areas like Europe, Asia-Pacific, North America and the rest of the world. The North American market contributed the highest revenue share in 2017 and is likely to continue its dominance throughout the forecast period. However, it is the Asia- Pacific market that is expected to witness the highest CAGR by the end of 2026.

COMPETITIVE INSIGHTS

Leading players in the global companion diagnostics market are Abbott Laboratories, Almac Group, Arup Laboratories, Biocartis, Biomerieux S.A, Danaher Corporation, Ge Healthcare, Genomic Health, Illumina Inc, Myriad Genetics Inc, Qiagen N.V, Roche Diagnostics (A Hoffmann-La Roche Ag Divison), Sysmex Corporation, and Thermo Fisher Scientific Inc.

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. ONCOLOGY MARKET TO HOLD THE LARGEST MARKET SHARE IN TERMS OF INDICATOR
    • 3.2.2. ASSAY KITS AND REAGENTS ARE SIGNIFICANTLY USED IN TERMS OF PRODUCT AND SERVICE
    • 3.2.3. RISING INCIDENCE OF CANCER GLOBALLY
    • 3.2.4. NEXT GENERATION SEQUENCING IS GROWING SIGNIFICANTLY

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. RISING DEMAND FOR TARGETED THERAPY
    • 4.1.2. INCREASING PREVALENCE OF CANCER
    • 4.1.3. RISING STRATEGIC INITIATIVES FOR COMPANION DIAGNOSTICS TEST DEVELOPMENT
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. ISSUES RELATED TO INTELLECTUAL PROPERTY RIGHTS
    • 4.2.2. REIMBURSEMENT ISSUES
  • 4.3. MARKET OPPORTUNITY
    • 4.3.1. FOCUSED ON IMPLEMENTING COMPANION DIAGNOSTICS DUE TO RISING NEW INDICATION AREAS
    • 4.3.2. GROWING DEMAND FOR NEXT-GENERATION SEQUENCING
    • 4.3.3. ESCALATING NUMBER OF CLINICAL TRIALS IN COMPANION DIAGNOSTICS
  • 4.4. MARKET CHALLENGES
    • 4.4.1. PROLONGED DEVELOPMENT TIME OF COMPANION DIAGNOSTICS
    • 4.4.2. LENGTHY APPROVAL PROCESS

5. MARKET SEGMENTATION

  • 5.1. MARKET BY PRODUCTS AND SERVICES 2018-2026
    • 5.1.1. ASSAY KITS AND REAGENTS
    • 5.1.2. SOFTWARE AND SERVICE
  • 5.2. MARKET BY INDICATION 2018-2026
    • 5.2.1. ONCOLOGY
    • 5.2.2. NEUROLOGY
    • 5.2.3. INFECTIOUS DISEASES
    • 5.2.4. OTHER INDICATIONS
  • 5.3. MARKET BY END USER 2018-2026
    • 5.3.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
    • 5.3.2. REFERENCE LABORATORIES
    • 5.3.3. OTHER END USERS
  • 5.4. MARKET BY TECHNOLOGY 2018-2026
    • 5.4.1. IN SITU HYBRIDIZATION
    • 5.4.2. POLYMERASE CHAIN REACTION
    • 5.4.3. IMMUNOHISTOCHEMISTRY
    • 5.4.4. NEXT GENERATION SEQUENCING
    • 5.4.5. OTHER TECHNOLOGIES

6. KEY ANALYTICS

  • 6.1. PORTER'S 5 FORCES ANALYSIS
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. ETYMOLOGY OF COMPANION DIAGNOSTICS
  • 6.3. SUPPLY CHAIN ANALYSIS
  • 6.4. KEY BUYING CRITERIA
  • 6.5. REGULATORY FRAMEWORK
  • 6.6. ESTIMATION ANALYSIS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. THE UNITED KINGDOM
    • 7.2.2. FRANCE
    • 7.2.3. GERMANY
    • 7.2.4. SPAIN
    • 7.2.5. ITALY
    • 7.2.6. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. INDIA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA
    • 7.3.5. SOUTH KOREA
    • 7.3.6. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST AND AFRICA

8. COMPANY PROFILES

  • 8.1. COMPETITIVE LANDSCAPE
  • 8.2. ABBOTT LABORATORIES.
    • 8.2.1. COMPANY OVERVIEW
    • 8.2.2. PRODUCT PORTFOLIO
    • 8.2.3. SCOT ANALYSIS
    • 8.2.4. STRATEGIC INITIATIVES
  • 8.3. ALMAC GROUP
    • 8.3.1. COMPANY OVERVIEW
    • 8.3.2. PRODUCT PORTFOLIO
    • 8.3.3. SCOT ANALYSIS
    • 8.3.4. STRATEGIC INITIATIVES
  • 8.4. ARUP LABORATORIES
    • 8.4.1. COMPANY OVERVIEW
    • 8.4.2. PRODUCT PORTFOLIO
    • 8.4.3. SCOT ANALYSIS
  • 8.5. BIOCARTIS
    • 8.5.1. COMPANY OVERVIEW
    • 8.5.2. PRODUCT PORTFOLIO
    • 8.5.3. SCOT ANALYSIS
    • 8.5.4. STRATEGIC INITIATIVES
  • 8.6. BIOMERIEUX S.A
    • 8.6.1. COMPANY OVERVIEW
    • 8.6.2. PRODUCT PORTFOLIO
    • 8.6.3. SCOT ANALYSIS
  • 8.7. DANAHER CORPORATION
    • 8.7.1. COMPANY OVERVIEW
    • 8.7.2. PRODUCT PORTFOLIO
    • 8.7.3. SCOT ANALYSIS
    • 8.7.4. STRATEGIC INITIATIVES
  • 8.8. GE HEALTHCARE
    • 8.8.1. COMPANY OVERVIEW
    • 8.8.2. PRODUCTS PORTFOLIO
    • 8.8.3. SCOT ANALYSIS
    • 8.8.4. STRATEGIC INITIATIVES
  • 8.9. GENOMIC HEALTH
    • 8.9.1. COMPANY OVERVIEW
    • 8.9.2. PRODUCT PORTFOLIO
    • 8.9.3. SCOT ANALYSIS
    • 8.9.4. STRATEGIC INITIATIVES
  • 8.10. ILLUMINA, INC.
    • 8.10.1. COMPANY OVERVIEW
    • 8.10.2. PRODUCT PORTFOLIO
    • 8.10.3. SCOT ANALYSIS
    • 8.10.4. STRATEGIC INITIATIVES
  • 8.11. MYRIAD GENETICS, INC.
    • 8.11.1. COMPANY OVERVIEW
    • 8.11.2. PRODUCT PORTFOLIO
    • 8.11.3. SCOT ANALYSIS
    • 8.11.4. STRATEGIC INITIATIVES
  • 8.12. QIAGEN N.V.
    • 8.12.1. COMPANY OVERVIEW
    • 8.12.2. PRODUCT PORTFOLIO
    • 8.12.3. SCOT ANALYSIS
    • 8.12.4. STRATEGIC INITIATIVES
  • 8.13. ROCHE DIAGNOSTICS (A HOFFMANN-LA ROCHE AG DIVISON)
    • 8.13.1. COMPANY OVERVIEW
    • 8.13.2. PRODUCT PORTFOLIO
    • 8.13.3. SCOT ANALYSIS
    • 8.13.4. STRATEGIC INITIATIVES
  • 8.14. SYSMEX CORPORATION
    • 8.14.1. COMPANY OVERVIEW
    • 8.14.2. PRODUCT PORTFOLIO
    • 8.14.3. SCOT ANALYSIS
    • 8.14.4. STRATEGIC INITIATIVES
  • 8.15. THERMO FISHER SCIENTIFIC, INC.
    • 8.15.1. COMPANY OVERVIEW
    • 8.15.2. PRODUCT PORTFOLIO
    • 8.15.3. SCOT ANALYSIS
    • 8.15.4. STRATEGIC INITIATIVES

TABLE LIST

  • TABLE 1 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 2 PERSONALIZED THERAPEUTICS APPROVED BY THE FDA
  • TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY PRODUCT AND SERVICE 2018-2026 ($ MILLION)
  • TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET IN ASSAY KITS AND REAGENTS BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 5 GLOBAL COMPANION DIAGNOSTICS MARKET IN SOFTWARE AND SERVICE BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 6 GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET IN ONCOLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET IN NEUROLOGY BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET IN INFECTIOUS DISEASES BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET IN OTHER INDICATIONS BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY END USER 2018-2026 ($ MILLION)
  • TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET IN PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET IN REFERENCE LABORATORIES BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET IN OTHER END USERS BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)
  • TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET IN IN SITU HYBRIDIZATION BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 17 GLOBAL COMPANION DIAGNOSTICS MARKET IN POLYMERASE CHAIN REACTION BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 18 GLOBAL COMPANION DIAGNOSTICS MARKET IN IMMUNOHISTOCHEMISTRY BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 19 GLOBAL COMPANION DIAGNOSTICS MARKET IN NEXT GENERATION SEQUENCING BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 20 GLOBAL COMPANION DIAGNOSTICS MARKET IN OTHER TECHNOLOGIES BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 21 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
  • TABLE 22 NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
  • TABLE 23 THE UNITED STATES COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 24 CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 25 EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
  • TABLE 26 THE UNITED KINGDOM COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 27 FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 28 GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 29 SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 30 ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
  • TABLE 31 CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 32 INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 33 JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 34 AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 35 REST OF WORLD COMPANION DIAGNOSTICS MARKET BY COUNTRIES 2018-2026 ($ MILLION)
  • TABLE 36 LATIN AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)
  • TABLE 37 MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION 2018-2026 ($ MILLION)

FIGURES LIST

  • FIGURE 1 GLOBAL COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 2 GROWING NUMBER OF PEOPLE WITH CANCER WORLDWIDE
  • FIGURE 3 SUPPLY CHAIN ANALYSIS OF COMPANION DIAGNOSTICS INDUSTRY
  • FIGURE 4 KEY BUYING CRITERIA
  • FIGURE 5 R&D SPENDING IN BIOPHARMACEUTICAL INDUSTRY GLOBALLY ($ BILLION)
  • FIGURE 6 NEWLY REGISTERED CLINICAL TRIAL STUDY 2016-2018
  • FIGURE 7 THE UNITED STATES COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 8 CANADA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 9 THE UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 10 FRANCE COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 11 GERMANY COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 12 SPAIN COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 13 ITALY COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 14 REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 15 CHINA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 16 INDIA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 17 JAPAN COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 18 AUSTRALIA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 19 SOUTH KOREA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 20 REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 21 LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 22 MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
  • FIGURE 23 COMPANY MARKET SHARE OF GLOBAL COMPANION DIAGNOSTICS MARKET 2017 (%)
Back to Top